:strip_icc()/i.s3.glbimg.com/v1/AUTH_63b422c2caee4269b8b34177e8876b93/internal_photos/bs/2020/E/v/AWDvKeR4u6z1SAZL0kjA/image.jpg)
[ad_1]
The National Health Surveillance Agency (Anvisa) reported this Friday that the laboratory inspection process ended today Sinovac, in China. The company is a partner of Butantan Institute in the supply of coronavac prepared vaccines – against covid-19 -, as well as the supplies for the production of the immunizer by the São Paulo institution in Brazil.
The visit of Anvisa technicians, whose objective was to verify good manufacturing practices, ended around 7 am today (Brasilia time).
“It is important to clarify that the conclusion of the process will occur with the issuance of the Inspection Report by the team of inspectors designated by Anvisa, after presenting additional information resulting from the inspection that will be sent by the Butantan Institute,” said the municipality in a note.
The forecast is that the Certification in Good Manufacturing Practices will be awarded between the last week of December and the first week of January, the agency explained.
Next week, Anvisa’s team of inspectors will carry out the inspection process at Wuxi Biologics Co, a company that produces the inputs used by Fiocruz Bio-Manguinhos in the production of the AstraZeneca vaccine.
The Anvisa inspectors left for China in mid-November and the inspection in Sinovac took place between November 30 and December 4.
